Correction to: Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer

被引：0
|
作者：
Puneet Saxena
Pawan Kumar Singh
Prabhat Singh Malik
Navneet Singh
机构：
[1] Postgraduate Institute of Medical Education and Research (PGIMER),Department of Pulmonary Medicine
[2] University of Health Sciences,Department of Pulmonary and Critical Care Medicine, Post Graduate Institute of Medical Sciences (PGIMS)
[3] All India Institute of Medical Sciences,Department of Medical Oncology, Dr. B.R.A.I.R.C.H
来源：
Current Treatment Options in Oncology | 2020年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The original version of this article unfortunately contained mistakes. In Table 2, under the column 'Lead to death' in Row 5 [CheckMate-026], the figures should read as '0.7' for Experimental Arm and '1.1' for Comparator. Right now, these are printed as 0.007 and 0.011 respectively.
引用
收藏
相关论文
共 50 条
  • [21] First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer A Systematic Review
    Goffin, John
    Lacchetti, Christina
    Ellis, Peter M.
    Ung, Yee C.
    Evans, William K.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (02) : 260 - 274
  • [22] The role of nivolumab combined to immunotherapy and/or chemotherapy in the first-line treatment of advanced Non Small Cell Lung Cancer
    Rocco, Danilo
    Della Gravara, Luigi
    Battiloro, Ciro
    Gridelli, Cesare
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (03) : 303 - 309
  • [23] Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer
    Chang, Myung Hee
    Kim, Kyoung Ha
    Jun, Hyun Jung
    Kim, Hyo Song
    Yi, Seong Yoon
    Uhm, Ji Eun
    Park, Min Jae
    Lim, Do Hyoung
    Ji, Sang Hoon
    Hwang, In Gyu
    Lee, Jeeyun
    Park, Yeon Hee
    Ahn, Jin Seok
    Ahn, Myung-ju
    Park, Keunchil
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (05) : 917 - 924
  • [24] Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer
    Myung Hee Chang
    Kyoung Ha Kim
    Hyun Jung Jun
    Hyo Song Kim
    Seong Yoon Yi
    Ji Eun Uhm
    Min Jae Park
    Do Hyoung Lim
    Sang Hoon Ji
    In Gyu Hwang
    Jeeyun Lee
    Yeon Hee Park
    Jin Seok Ahn
    Myung-ju Ahn
    Keunchil Park
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 917 - 924
  • [25] Cisplatin plus docetaxel combination in the first-line treatment of metastatic non-small cell lung cancer
    Kaya, Ali Osman
    Buyukberber, Suleyman
    Dane, Faysal
    Isikdogan, Abdurrahman
    Ustaalioglu, Basak Oven
    Coskun, Ugur
    Yumuk, Perran Fulden
    Dogu, Gamze Gokoz
    Ozdemir, Nuriye Yildirim
    Sevinc, Alper
    Gumus, Mahmut
    Ozkan, Metin
    Yildiz, Ramazan
    Ozturk, Banu
    Yaman, Emel
    Benekli, Mustafa
    TUMORI JOURNAL, 2010, 96 (03): : 400 - 404
  • [26] First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly
    Losanno, Tania
    Gridelli, Cesare
    CURRENT ONCOLOGY REPORTS, 2021, 23 (10)
  • [27] Bevacizumab as first-line treatment for advanced non-small cell lung cancer
    Socinski, Mark A.
    DRUGS OF TODAY, 2008, 44 (04) : 293 - 301
  • [28] The use of pemetrexed for the first-line treatment of non-small cell lung cancer
    Silva, S.
    Colquitt, J.
    Hatton, M. Q.
    Mohanamurali, J.
    Lee, C.
    Danson, S.
    Fisher, P.
    Woll, P.
    LUNG CANCER, 2014, 83 : S13 - S13
  • [29] First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly
    Tania Losanno
    Cesare Gridelli
    Current Oncology Reports, 2021, 23
  • [30] Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
    Wang, Xue
    Niu, Xiaomin
    An, Na
    Sun, Yile
    Chen, Zhiwei
    FRONTIERS IN ONCOLOGY, 2021, 11
12345